All In Biotech

Drug Trial Radar · NCT05409027

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jul 23, 2021

Primary completion

Mar 10, 2022

Study completion Feb 7, 2024

Sponsor

Lead sponsor
Sparrow PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)

Conditions

  • Type 2 Diabetes Mellitus in Obese
  • Obesity
  • Type2Diabetes

Interventions

  • SPI-62Drug

    SPI-62 is supplied as 1 mg tablets for oral dosing.

  • Cortisone-d8Drug

    Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (Cmax)Time frame: Days 1 through 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ProSciento

    Chula Vista, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.